PT2982372T - Agentes moduladores do glutamato no tratamento de distúrbios mentais - Google Patents
Agentes moduladores do glutamato no tratamento de distúrbios mentaisInfo
- Publication number
- PT2982372T PT2982372T PT151825627T PT15182562T PT2982372T PT 2982372 T PT2982372 T PT 2982372T PT 151825627 T PT151825627 T PT 151825627T PT 15182562 T PT15182562 T PT 15182562T PT 2982372 T PT2982372 T PT 2982372T
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- mental disorders
- modulating agents
- glutamate modulating
- glutamate
- Prior art date
Links
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
- 229930195712 glutamate Natural products 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/10—Optical coatings produced by application to, or surface treatment of, optical elements
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B5/00—Optical elements other than lenses
- G02B5/20—Filters
- G02B5/28—Interference filters
- G02B5/281—Interference filters designed for the infrared light
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B5/00—Optical elements other than lenses
- G02B5/20—Filters
- G02B5/28—Interference filters
- G02B5/283—Interference filters designed for the ultraviolet
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B5/00—Optical elements other than lenses
- G02B5/20—Filters
- G02B5/28—Interference filters
- G02B5/285—Interference filters comprising deposited thin solid films
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L27/00—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate
- H01L27/14—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation
- H01L27/144—Devices controlled by radiation
- H01L27/146—Imager structures
- H01L27/14601—Structural or functional details thereof
- H01L27/1462—Coatings
- H01L27/14621—Colour filter arrangements
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L27/00—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate
- H01L27/14—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation
- H01L27/144—Devices controlled by radiation
- H01L27/146—Imager structures
- H01L27/14683—Processes or apparatus peculiar to the manufacture or treatment of these devices or parts thereof
- H01L27/14685—Process for coatings or optical elements
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66873505P | 2005-04-05 | 2005-04-05 | |
US66977405P | 2005-04-07 | 2005-04-07 | |
US69018705P | 2005-06-13 | 2005-06-13 | |
US69462105P | 2005-06-27 | 2005-06-27 | |
US75647206P | 2006-01-04 | 2006-01-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2982372T true PT2982372T (pt) | 2020-10-09 |
Family
ID=36659964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT151825627T PT2982372T (pt) | 2005-04-05 | 2006-04-05 | Agentes moduladores do glutamato no tratamento de distúrbios mentais |
Country Status (11)
Country | Link |
---|---|
US (7) | US8778979B2 (pt) |
EP (4) | EP2982372B1 (pt) |
CY (1) | CY1124111T1 (pt) |
DK (1) | DK2201963T3 (pt) |
ES (2) | ES2564187T3 (pt) |
HU (1) | HUE050758T2 (pt) |
LT (1) | LT2982372T (pt) |
PL (1) | PL2982372T3 (pt) |
PT (1) | PT2982372T (pt) |
SI (1) | SI2982372T1 (pt) |
WO (1) | WO2006108055A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006081332A1 (en) | 2005-01-25 | 2006-08-03 | Epix Delaware, Inc. | Substituted arylamine compounds and their use as 5-ht6 modulators |
US8778979B2 (en) | 2005-04-05 | 2014-07-15 | Yale University | Glutamate agents in the treatment of mental disorders |
JP2010507572A (ja) * | 2006-10-23 | 2010-03-11 | ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア | 併用療法 |
US8604080B2 (en) * | 2007-02-14 | 2013-12-10 | W. Louis Cleveland | High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders |
EP2018854A1 (en) * | 2007-07-27 | 2009-01-28 | Merz Pharma GmbH & Co. KGaA | Novel combinations of neramexane for the treatment of neurodegenerative disorders |
US7829709B1 (en) | 2007-08-10 | 2010-11-09 | Marquette University | Cysteine prodrugs to treat schizophrenia and drug addiction |
EP2252596B1 (en) * | 2008-02-07 | 2016-12-28 | Marquette University | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings |
TW201006463A (en) * | 2008-06-26 | 2010-02-16 | Merz Pharma Gmbh & Co Kgaa | Pharmaceutical compositions comprising aminocyclohexane derivatives |
US8633233B2 (en) * | 2008-08-06 | 2014-01-21 | Hydra Biosciences, Inc. | Methods and compositions for treating anxiety |
AU2010213683B2 (en) | 2009-02-12 | 2016-04-21 | Indiana University Research & Technology Corporation | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
KR101401744B1 (ko) * | 2010-09-06 | 2014-06-02 | 서울대학교산학협력단 | N-아세틸-l-시스테인 또는 이의 유도체를 포함하는 불안 장애 치료용 약학 조성물 |
US20120270860A1 (en) * | 2011-04-19 | 2012-10-25 | Gihyun Yoon | Methods for treating or preventing alcohol-related disorders or craving-related disorders |
MX2017011196A (es) | 2015-03-03 | 2018-05-22 | Biohaven Pharm Holding Co Ltd | Farmacos precursores de riluzol y sus usos. |
WO2016184911A1 (en) * | 2015-05-18 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of the neuropathology of patients suffering from myotonic dystrophy type 1 (dm1) |
EA202190544A1 (ru) * | 2018-08-16 | 2021-06-18 | Биохэйвен Терапьютикс Лтд. | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний |
AU2021297249A1 (en) * | 2020-06-24 | 2023-02-23 | Biohaven Therapeutics Ltd. | Compositions and methods for treating obsessive-compulsive disorder |
WO2024054811A1 (en) * | 2022-09-06 | 2024-03-14 | Biohaven Therapeutics Ltd. | Combination therapies including metal channel activators |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
US5310897A (en) | 1984-12-27 | 1994-05-10 | Sumitomo Pharmaceuticals Co., Ltd. | Beta-lactams and their production |
EP0241809B1 (de) | 1986-04-16 | 1990-08-08 | ASTA Pharma Aktiengesellschaft | Synergistische Kombination von Amantadin und Selegilin |
FR2619712B1 (fr) * | 1987-08-25 | 1990-08-31 | Rhone Poulenc Sante | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie |
WO1991006291A1 (en) | 1989-10-26 | 1991-05-16 | Nippon Shinyaku Co., Ltd. | Sustained release preparation |
EP0502036B1 (en) | 1989-11-22 | 1995-12-20 | Genentech, Inc. | Latency associated peptide and uses therefor |
US5190763A (en) | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5221536A (en) | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5192550A (en) | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
US5057321A (en) | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
US5104761A (en) | 1990-09-14 | 1992-04-14 | Eastman Kodak Company | Interdispersed three-phase ferrite composite and electrographic magnetic carrier particles therefrom |
US5358721A (en) | 1992-12-04 | 1994-10-25 | Alza Corporation | Antiviral therapy |
FR2702148B1 (fr) * | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
JP4863534B2 (ja) | 1996-10-25 | 2012-01-25 | スパーナス ファーマシューティカルズ インコーポレイテッド | 可溶形態浸透用量送達システム |
US6057373A (en) * | 1997-05-22 | 2000-05-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
US5866585A (en) * | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
US5952389A (en) * | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
US6294583B1 (en) * | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
US6391922B1 (en) * | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
KR20010043630A (ko) * | 1998-05-15 | 2001-05-25 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 치매의 치료를 위한 글루코코티코이드 수용체 길항제 |
US6031094A (en) | 1998-07-23 | 2000-02-29 | The Regents Of The University Of California | Beta-lactam substrates and uses thereof |
US6387956B1 (en) * | 1999-03-24 | 2002-05-14 | University Of Cincinnati | Methods of treating obsessive-compulsive spectrum disorders |
DE60041365D1 (de) * | 1999-06-04 | 2009-02-26 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Verwendung von Riluzol zur Behandlung Multipler Sklerose |
US6228888B1 (en) * | 1999-07-01 | 2001-05-08 | Guilford Pharmaceuticals Inc. | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
EP1212055B1 (en) | 1999-08-16 | 2011-08-03 | Revaax Pharmaceuticals LLC | Neurotherapeutic composition comprising a beta-lactam compound |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6362226B2 (en) * | 1999-12-08 | 2002-03-26 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
GB0005700D0 (en) * | 2000-03-09 | 2000-05-03 | Glaxo Group Ltd | Therapy |
JP2001328947A (ja) * | 2000-05-19 | 2001-11-27 | Ritsuko Senba | 脳由来神経栄養因子発現促進剤 |
US6566401B2 (en) | 2001-03-30 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
US20030162694A1 (en) * | 2002-02-04 | 2003-08-28 | James Meyerhoff | Novel treatment for pathological aggression |
EP1595535A2 (en) | 2002-12-23 | 2005-11-16 | Osmotica Costa Rica Sociedad Anonima | Delivery device containing venlafaxine and memantine and use method thereof |
US20060121488A1 (en) * | 2003-02-26 | 2006-06-08 | Rothstein Jeffrey D | Glutamate transport modulatory compounds and methods |
AR043467A1 (es) | 2003-03-05 | 2005-07-27 | Osmotica Argentina S A | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson |
CA2525366A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
US8252331B2 (en) | 2004-12-03 | 2012-08-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Osmotic device containing amantadine and an osmotic salt |
AR053986A1 (es) | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | Dispositivo osmotico que contiene amantadina y una sal osmotica |
US20060167068A1 (en) | 2005-01-26 | 2006-07-27 | Seth Feuerstein | Method of treating self-injurious behavior with glutamate modulating agents |
US8778979B2 (en) | 2005-04-05 | 2014-07-15 | Yale University | Glutamate agents in the treatment of mental disorders |
KR100748513B1 (ko) | 2005-10-07 | 2007-08-14 | 엘지전자 주식회사 | 위치 서비스 방법 및 시스템 |
CA2625210A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
EP2363119A1 (fr) * | 2010-03-05 | 2011-09-07 | Centre Hospitalier Universitaire d'Angers | Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires |
-
2006
- 2006-04-05 US US11/399,188 patent/US8778979B2/en active Active
- 2006-04-05 EP EP15182562.7A patent/EP2982372B1/en active Active
- 2006-04-05 ES ES10156331.0T patent/ES2564187T3/es active Active
- 2006-04-05 HU HUE15182562A patent/HUE050758T2/hu unknown
- 2006-04-05 SI SI200632386T patent/SI2982372T1/sl unknown
- 2006-04-05 EP EP20189325.2A patent/EP3753561A1/en active Pending
- 2006-04-05 PL PL15182562T patent/PL2982372T3/pl unknown
- 2006-04-05 ES ES15182562T patent/ES2819303T3/es active Active
- 2006-04-05 PT PT151825627T patent/PT2982372T/pt unknown
- 2006-04-05 EP EP06749354A patent/EP1874353A1/en not_active Ceased
- 2006-04-05 LT LTEP15182562.7T patent/LT2982372T/lt unknown
- 2006-04-05 DK DK10156331.0T patent/DK2201963T3/en active
- 2006-04-05 EP EP10156331.0A patent/EP2201963B1/en active Active
- 2006-04-05 WO PCT/US2006/012701 patent/WO2006108055A1/en active Application Filing
-
2014
- 2014-05-15 US US14/278,573 patent/US10052318B2/en active Active
-
2017
- 2017-09-05 US US15/695,164 patent/US20170360775A1/en not_active Abandoned
-
2018
- 2018-07-10 US US16/031,250 patent/US11554117B2/en active Active
-
2020
- 2020-09-29 CY CY20201100917T patent/CY1124111T1/el unknown
- 2020-12-07 US US17/247,285 patent/US20210093630A1/en not_active Abandoned
- 2020-12-07 US US17/247,278 patent/US20210093629A1/en active Pending
-
2021
- 2021-06-04 US US17/339,530 patent/US20210294011A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PL2982372T3 (pl) | 2020-12-28 |
US20060270647A1 (en) | 2006-11-30 |
EP2982372B1 (en) | 2020-08-05 |
US20170360775A1 (en) | 2017-12-21 |
US20210093630A1 (en) | 2021-04-01 |
ES2819303T3 (es) | 2021-04-15 |
WO2006108055A1 (en) | 2006-10-12 |
ES2564187T3 (es) | 2016-03-18 |
EP2201963B1 (en) | 2016-01-27 |
EP3753561A1 (en) | 2020-12-23 |
EP1874353A1 (en) | 2008-01-09 |
US20210294011A1 (en) | 2021-09-23 |
CY1124111T1 (el) | 2022-03-24 |
US11554117B2 (en) | 2023-01-17 |
US10052318B2 (en) | 2018-08-21 |
LT2982372T (lt) | 2020-10-26 |
US20180318288A1 (en) | 2018-11-08 |
HUE050758T2 (hu) | 2021-01-28 |
EP2982372A1 (en) | 2016-02-10 |
US20140249173A1 (en) | 2014-09-04 |
DK2201963T3 (en) | 2016-02-15 |
SI2982372T1 (sl) | 2020-11-30 |
US8778979B2 (en) | 2014-07-15 |
US20210093629A1 (en) | 2021-04-01 |
EP2201963A1 (en) | 2010-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2982372T3 (pl) | Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych | |
IL184363A0 (en) | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | |
ZA200806114B (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
AP3091A (en) | Agents for preventing and treating disorders involving modulation of the RYR receptors | |
IL195819A0 (en) | Modulators of metabolism and the treatment of disorders related thereto | |
IL195851A0 (en) | Modulators of metabolism and the treatment of disorders related thereto | |
IL195906A0 (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
IL188204A0 (en) | Combination therapy for the treatment of immunoinflammatory disorders | |
IL180078A (en) | Derivatives of 9-cis retinal for use in treating deficiency of 11-cis retinal | |
IL208607A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
ME01219B (me) | Alfa-aminoamid derivati korisni u liječenju bolesti zavisnosti | |
IL188390A0 (en) | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | |
IL181777A0 (en) | Gpr43 and modulators thereof for the treatment of metabolic-related disorders | |
ZA200800409B (en) | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | |
PL2066314T3 (pl) | Zastosowanie teogaliny do leczenia umysłowych zaburzeń zdolności do koncentracji, depresji i demencji | |
GB0419828D0 (en) | The treatment of inflammatroy disorders and pain | |
HK1125634A1 (en) | Pharmaceutical for use in the treatment of ureterolithiasis |